Safety of inhalant allergen immunotherapy with mass units-standardized extracts

Clinical and Experimental Allergy

Volumn 32, Issue 12, 2002, Pages 1745-1749

  Nettis, Eustachio ^a,b   Giordano, D ^a   Pannofino, A ^a   Ferrannini, A ^a   Tursi, A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Allergen specific immunotherapy; Asthma; Dose increase; Mass units; Serious systemic reactions

Indexed keywords

GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; OLIVE OIL; PANGRAMIN; PARIETARIA JUDAICA EXTRACT; POLLEN EXTRACT; UNCLASSIFIED DRUG; ALLERGEN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; SKIN TEST; TREATMENT OUTCOME; AGE; ASTHMA; CHILD; CLINICAL TRIAL; DESENSITIZATION; DOSE RESPONSE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; POLLEN; PYROGLYPHIDAE; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGE FACTORS; ALLERGENS; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; POLLEN; PYROGLYPHIDAE; RHINITIS; RISK FACTORS; SKIN TESTS;

EID: 0036456755     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2002.01544.x     Document Type: Article

References (24)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572-3.
2. Freeman J. Vaccination against hay fever: Report of results during the first three years. Lancet 1914; 1:1178.
3. Malling H-J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53:461-72.
4. Malling H-J, Weeke B. EAACI position paper. Immunotherapy Allergy 1993; 48 (Suppl. 14):9-35.
5. Bousquet J, Lockey RF, Malling H-J, eds. WHO position paper allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl. 44):142.
6. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-77.
7. Reid M J, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985-89. J Allergy Clin Immunol 1993; 92:6-15.
8. Committee on Safety in Medicine. Desensitizing vaccines. Br Med J 1986; 293:948.
9. Norman PS, An overview of immunotherapy implications for the future. J Allergy Clin Immunol 1980; 65:87-96.
10. Van Metre TE, Adkinson NF Jr, Amodio FJ et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980; 66:500-13.
11. Norman PS. Immunotherapy. Prog Allergy 1981; 32:318-55.
12. Dreborg S, Backman A, Basomba A et al. Skin tests used in type I allergy testing. Position paper prepared by the Subcommittee on Skin Tests of the EAACI. Allergy 1989; 44 (Suppl. 10): 1-59.
13. Lombardero M, Gonzáles R, Duffort O et al. Evaluación de la actividad biológica total y composición alergénica de extractos alergénicos. Allergol Immunophatol (Madr) 1986; 14:189-98.
14. Ventas P, Lombardero M, Duffort O, Carreira J. Cuantificación de los alergenos Der p 1 y Der f 1 de los ácaros del polvo doméstico y Fel d 1 de gato, mediante un ELISA en fase sólida. Rev Esp Alergol Immunol Clin 1990; 5:71.
15. Ramirez J, Obispo TM, Duffort D et al. Group 5 determination in Pooideae grass pollen extracts by monoclonal antibody-based ELISA. Correlation with biologic activity. Allergy 1997; 52:806-13.
16. Lauzurica P, Maruri N, Galocha B et al. Olive (Olea europea) pollen allergens - II. Isolation and characterization of two major antigens. Mol Immunol 1988; 25:337-44.
17. Corbi AL, Ayuso R, Lombardero M, Duffort O, Carreira J. A competitive solid-phase radioimmunoassay for quantitation of the major allergen of Parietaria pollen. J Immunol Meth 1985; 83:83-8.
18. Mellerup MT, Hahn GW, Poulsen LK, Malling H-J. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423-9.
19. D'Amato G, Lobefalo G. Allergenic pollens in the southern Mediterranean area. J Allergy Clin Immunol 1989; 83:116-22.
20. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48:450-3.
21. Greenberg MA, Kaufman CR, Gonzáles GE, Rosenblatt CD, Smith L J, Summers RJ. Late and immediate systemic allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986; 77:865-70.
22. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71:557-62.
23. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy 1986; 56:3314.
24. Rieckenberg MR, Khan RH, Day JH. Physician reported patient response immunotherapy: A retrospective study of factors affecting the response. Ann Allergy 1990; 64:364-7.